Research and Markets: Royalty Rates for Pharmaceuticals & Biotechnology, 7th Edition

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/24225f/royalty_rates_for) has announced the addition of the "Royalty Rates for Pharmaceuticals & Biotechnology, 7th Edition" report to their offering.

Patented technology is the coveted crown jewel of the pharmaceutical and biotechnology industry. Pharmaceutical companies are aggressively pursuing new technologies and products regardless of their source. The amounts being paid for acquisition and licensing of new technologies, molecules and products is rising as pharmaceutical companies, with empty research pipelines, frantically compete for new technologies.

This report is a tool that can be used to optimize the pricing of biotechnology and pharmaceutical intellectual property. The information in this resource is also useful for the valuation of patents and establishing damages for infringement litigation. The seventh edition of Royalty Rates for Pharmaceuticals & Biotechnology continues to focus on the royalty rates associated with biotechnology and pharmaceutical intellectual property transfers. This report is organized into two parts. The first part covers the theory associated with deriving royalty rates. An overview of intellectual property value is provided along with various methods that can be employed to derive royalty rates from financial analysis. The methods discussed are both qualitative and quantitative.

The second part of this report presents detailed financial information about real world third-party transactions that center on the transfer of biotechnology and pharmaceutical intellectual property. The parties involved in the transactions are disclosed along with a description of the technology exchanged and all of the financial details that could be discovered. For this seventh edition we have emphasized the reporting of royalty rates and other financial compensation, associated with license agreements. We have updated and expanded information that was reported in past editions and conducted extensive research to expand the number of license agreements reported. The transaction information presented in this new edition has been collected from well-established sources believed to be reliable from September 1990 through August 2010.

Early-stage technology has typically commanded royalty rates and license fees that are relatively low. The risky and expensive nature of developing pharmaceutical and biotechnology coupled with the long lead-time between discovery and commercialization provides significant downward pressure on royalty rates and license fees. However, when clinical trials and/or regulatory hurdles are passed, a successful commercialized therapy, available for licensing, commands double-digit royalty rates and enormous license fees.

The remainder of this book shows methods for valuing and pricing the patented technology of the pharmaceutical and biotechnology industry and includes specific real world royalty rates.

Key Topics Covered:

  • Very Unique Assets
  • Business Enterprise Framework
  • Driving Forces Behind Royalty Rates
  • Simplistic Rules of Thumb
  • Royalty Rates and Industry Guidelines
  • Infringement Damages Analysis
  • Generic Pricing
  • Comparable License Transactions
  • Investment Rate of Return Analysis
  • Discounted Cash Flow Analysis
  • Risk Adjusted Net Present Value
  • Key Components of License Agreements
  • Alcohol Dependency Treatment
  • Anesthetic
  • Animal Health Products
  • Antibodies - Primatized
  • Antibodies - Primatized Anti-CD4
  • Anti-hypertension Therapy
  • Anti-infection Screening Process
  • Anti-inflammatory Drug BB-882
  • Anti-inflammatory Topical
  • Antifungal Agent Amphotericin B
  • Antifungal
  • Anti-retroviral medicine - Viread
  • Anti-viral Therapy
  • Anti-viral and Anti-infective Therapies
  • Arginine Products
  • Company Index
  • + Others

For more information visit http://www.researchandmarkets.com/research/24225f/royalty_rates_for



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.